A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Conditions
Colitis Ulcerative · Ulcerative Colitis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Clinnova Research ( Site 1042), Anaheim, California, United States
Peak Gastroenterology Associates ( Site 1052), Colorado Springs, Colorado, United States
South Denver Gastroenterology, PC ( Site 1068), Englewood, Colorado, United States
Nature Coast Clinical Research ( Site 1045), Inverness, Florida, United States
Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072), Miami, Florida, United States
Gastroenterology Associates of Central Georgia ( Site 1060), Macon, Georgia, United States
University of Kansas Medical Center ( Site 1077), Kansas City, Kansas, United States
Tulane University School of Medicine ( Site 1073), New Orleans, Louisiana, United States
BVL Research - Kansas ( Site 1054), Liberty, Missouri, United States
Radboudumc ( Site 1650), Nijmegen, Gelderland, Netherlands
Wonju Severance Christian Hospital ( Site 1602), Wŏnju, Kang-won-do, South Korea
Korea University Ansan Hospital ( Site 1603), Ansan-si, Kyonggi-do, South Korea
Kangbuk Samsung Hospital ( Site 1601), Seoul, South Korea
Study leads
Medical Director
Study Director
Merck Sharp & Dohme LLC